Chugai Pharmaceutical Co Ltd (4519.T)
1,988JPY
1 Aug 2013
¥43 (+2.21%)
¥2,085
¥1,938
¥1,997
¥1,938
1,092,100
1,431,955
¥2,550
¥1,497
About
Overall
| Beta: | 0.68 |
| Market Cap (Mil.): | ¥1,088,589.00 |
| Shares Outstanding (Mil.): | 559.69 |
| Dividend: | 23.00 |
| Yield (%): | 2.16 |
Financials
| 4519.T | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 20.35 | 37.93 | 37.76 |
| EPS (TTM): | 95.57 | -- | -- |
| ROI: | 10.14 | 19.48 | 18.76 |
| ROE: | 10.25 | 20.17 | 19.59 |
REFILE-TABLE-Chugai Pharm -6-MTH group results (IFRS)
(Adds company forecast) Jul 25 - Chugai Pharmaceutical Co Ltd CONSOLIDATED FINANCIAL HIGHLIGHTS (in billions of yen unless specified) 6 months ended 6 months ended Year to Jun 30, 2013 Jun 30, 2012 Dec 31, 2013 LATEST YEAR-AGO COMPANY RESULTS RESULT FORECAST Sales 201.02 185
Sony to name Chugai Pharma's CEO as chairman-Nikkei
May 18 - Sony Corp plans to appoint Chugai Pharmaceutical Co Chief Executive Osamu Nagayama as chairman, the Nikkei reported.
Roche says no plans to change holding in Japan's Chugai
LONDON, April 11 - Swiss drugmaker Roche has no plans to change its holding in Japan's Chugai Pharmaceutical and the recent weakening of the yen would not be a reason to trigger such a move.
Roche says Japan approves new formulation of arthritis drug
ZURICH - Roche Holding AG's Japanese subsidiary Chugai said on Monday that Japanese health regulators have approved a new formulation of its rheumatoid arthritis drug Actemra.
Roche says Japan approves new formulation of arthritis drug
ZURICH, March 25 - Roche Holding AG's Japanese subsidiary Chugai said on Monday that Japanese health regulators have approved a new formulation of its rheumatoid arthritis drug Actemra.
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$472.00
|
|
Provider: Datamonitor
|
$175.00
|
|
Provider: GlobalData
|
$125.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

